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Background: Visceral fat accumulation is a major etiological factor in the progression of type 2 diabetes mellitus
and atherosclerosis. We described previously visceral fat accumulation and multiple cardiovascular risk factors in
a considerable number of Japanese non-obese subjects (BMI <25 kg/m2). Here, we investigated differences in
systemic arteriosclerosis, serum adiponectin concentration, and eating behavior in type 2 diabetic patients with
and without visceral fat accumulation.
Methods: The study subjects were 75 Japanese type 2 diabetes mellitus (age: 64.8 ± 11.5 years, mean ± SD). Visceral
fat accumulation represented an estimated visceral fat area of 100 cm2 using the bioelectrical impedance analysis
method. Subjects were divided into two groups; with (n = 53) and without (n = 22) visceral fat accumulation.
Systemic arteriosclerosis was scored for four arteries by ultrasonography. Eating behavior was assessed based on
The Guideline for Obesity questionnaire issued by the Japan Society for the Study of Obesity.
Results: The visceral fat accumulation (+) group showed significantly higher systemic vascular scores and significantly
lower serum adiponectin levels than the visceral fat accumulation (−) group. With respect to the eating behavior
questionnaire items, (+) patients showed higher values for the total score and many of the major sub-scores than
(−) patients.
Conclusions: Type 2 diabetic patients with visceral fat accumulation showed 1) progression of systemic arteriosclerosis,
2) low serum adiponectin levels, and 3) differences in eating behavior, compared to those without visceral fat
accumulation. Taken together, the findings highlight the importance of evaluating visceral fat area in type 2 diabetic
patients. Furthermore, those with visceral fat accumulation might need to undergo more intensive screening for
systemic arteriosclerosis and consider modifying their eating behaviors.
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Eating behaviorBackground
Type 2 diabetes mellitus accelerates the process of arterio-
sclerosis and may result in severe cardiovascular events.
Since a variety of etiological factors seem to contribute to
type 2 diabetes mellitus, it is important to understand the
etiology in each patient and detect potential arteriosclerosis* Correspondence: hitoshin1127@endmet.med.osaka-u.ac.jp
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unless otherwise stated.at an early stage. In type 2 diabetes, arteriosclerosis is a
polyvascular and multifocal disease that can advance
without overt symptoms, making early prediction of
coronary artery diseases (CAD) important for the pre-
vention of cardiovascular events in these patients. We
have recently reported that quantification of the severity
of arteriosclerosis by vascular ultrasonography is a useful
tool for predicting CAD, and that the metabolic syndrome
was a significant determinant of total systemic vascular
score of ≥2 [1].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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betes mellitus has increased worldwide, especially in Asia
[2-5]. We reported previously that a considerable propor-
tion of non-obese (body mass index (BMI) <25 kg/m2)
Japanese subjects have visceral fat accumulation (visceral
fat area (VFA) ≥100 cm2), as well as multiple risk factors
of cardiovascular diseases, and that reduction of VFA
was significantly associated with a decrease in total cardio-
vascular risk [6]. Patients with visceral fat accumulation
also show dysregulation of adipocytokines, such as
hypoadiponectinemia, which is associated with type 2
diabetes mellitus and CAD [7-9]. Adiponectin is an
adipose-specific endocrine factor that exhibits anti-
diabetic, anti-atherogenic, and anti-inflammatory proper-
ties. It is therefore possible that type 2 diabetic patients
with visceral fat accumulation may be more affected by
arteriosclerosis, although there is little evidence to confirm
or deny this hypothesis.
In modifying the lifestyle of patients with obesity, cogni-
tive behavioral therapy is important in addition to diet and
exercise therapy [10], and research findings show a relation-
ship between eating behavior and obesity/weight gain [11].
It is therefore important to help each patient identify and
improve eating behavior problems. In the present study, we
investigated differences in the clinical features of Japanese
type 2 diabetic patients with and without visceral fat accu-
mulation, focusing on systemic arteriosclerosis, serum adi-
ponectin concentration, and eating behavior.
Methods
Subjects
The study subjects were selected from April 2012 to De-
cember 2012 among inpatients hospitalized for the con-
trol type 2 diabetes at the Division of Endocrinology and
Metabolism of Osaka University Hospital, and outpa-
tients who visited the “Diabetes & Metabolic Station”
outpatient clinic of Osaka University Hospital. Written
consent was obtained from each subject after explaining
the purpose and possible complications of the study.
This study complied with the Guidelines of the Ethnical
Committees of Osaka University. Type 2 diabetes was
defined according to the World Health Organization
(WHO) national diabetic group criteria of 2006 and/or
treatment of diabetes. The following patients were
excluded: 1) patients in whom waist circumference (WC)
and estimated visceral fat area (eVFA; see ‘Clinical exam-
ination’) was not measured, 2) patients who were not
clinically diagnosed with type 2 diabetes mellitus.
Clinical examination
Height, weight, and WC were measured in the standing
position (in inpatients, these data were measured on
admission). The bioelectrical impedance analysis method
was used to measure eVFA, which we showed previously tocorrelate significantly with VFA determined by computed
tomography [12]. The duration of diabetes was retrieved
through medical interview. Systolic/diastolic blood pressure
(BP) was measured with a standard mercury sphygmo-
manometer on the right arm in the supine position after
at least 10 minutes of rest. Venous blood samples were
collected in the morning after overnight fasting for
measurements of glucose and HbA1c (National Glyco-
hemoglobin Standardization Program (NGSP)), serum
C-peptide, lipids, creatinine, and uric acid (UA). Estimated
glomerular filtration rate (eGFR) was calculated using the
simplified Modification of Diet in Renal Disease equation
modified by the appropriate coefficient for Japanese
populations by gender [13]. The serum samples obtained
at baseline from each participant were stored promptly
at −20°C. After thawing, serum levels of total adiponectin
in 62 patients were measured by enzyme-linked im-
munosorbent assay (ELISA) (human adiponectin ELISA
kit, Otsuka Pharmaceutical Co. Tokushima, Japan), as
reported previously [14]. Urinary albumin-creatinine
ratio (uACR) was calculated from a single spot urine
specimen collected in the morning. The maximum or mean
intima-media thickness (IMT) of the common carotid
artery was measured in supine position by echography
as described previously [15,16].
Definition of visceral fat accumulation, diabetic retinopathy,
diabetic nephropathy, hypertension, dyslipidemia, and
metabolic syndrome
Visceral fat accumulation was defined as eVFA ≥100 cm2
[17,18]. Diabetic retinopathy was assessed by an ophthal-
mologist, and based on this we divided patients into two
groups (NDR and SDR/PrePDR/PDR). Diabetic nephropa-
thy was diagnosed when the uACR was ≥30 mg/g creatin-
ine. Hypertension was defined by systolic BP ≥140 mmHg
and/or diastolic BP ≥90 mmHg. Dyslipidemia was defined
as low-density lipoprotein cholesterol (LDL-C) concentra-
tions ≥140 mg/dl, triglyceride (TG) concentrations ≥150
mg/dl, and/or high-density lipoprotein cholesterol (HDL-C)
concentrations ≥40 mg/dL. Patients were considered posi-
tive for hypertension and/or dyslipidemia if they received
antihypertensive and/or anti-dyslipidemic medications,
respectively. Metabolic syndrome was defined as follows:
1) eVFA ≥100 cm2 and 2) positive for hypertension or
dyslipidemia (except for the criteria of LDL-C). This
definition was based on the Japanese guidelines for meta-
bolic syndrome [19], using eVFA instead of WC.
Questionnaire for eating behavior
Eating behavior was assessed in patients by using the
questionnaire of The Guideline For Obesity issued by the
Japan Society for the Study of Obesity, as in our previous
reports [20,21]. Briefly, this questionnaire comprises 55-
item questions of seven major scales as follows: 1)
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behavior, 3) emotional eating behavior, 4) sense of hunger,
5) eating style, 6) food preference, and 7) regularity of
eating habits. All items were rated on a four-point scale
ranging from 1 (seldom) to 4 (very often).
Evaluation of systemic vascular score
Among all study patients, 67 subjects were scored as hav-
ing systemic arteriosclerosis by vascular ultrasonography,
as per our previous report [15]. Briefly, we qualitatively
evaluated the presence of systemic arteriosclerosis by
systemic vascular ultrasonography using an ultrasound
scanner, evaluating the vessel interior of the following
four arteries: 1) common carotid arteries (for existence
of plaque, calcification), 2) renal arteries (stenosis), 3)
abdominal aorta between the diaphragm and bifurcation
of the common iliac arteries (plaque, calcification,
aneurysm), and 4) common iliac arteries (plaque, calci-
fication). Plaques in the aortic and common iliac artery
walls were considered present when the intimal surface
was not smooth and >1 mm in thickness. Renal arterial
stenosis was diagnosed by a peak systolic velocity of
more than 200 cm/sec with post-stenotic turbulence or
renal aortic flow velocity ratio. The score was set as 1
for an abnormality on either side in carotid, renal, and
common iliac arteries (0 to 4).
Statistical analysis
Data are presented as mean ± SD. First, Shapillo-Wilk’s W
test was used to determine the distribution of each param-
eter. Next, the difference between groups in systolic BP,
diastolic BP, LDL-C, HDL-C, and UA (i.e., variables with
normal distribution) were analyzed with Welch’s t-test.
For the other parameters (variables with skewed distribu-
tion), Mann-Whitney’s U test was used. We performed
the Cochran-Armitage trend test to analyze relationships
between the systemic vascular score groups. Fischer’s
exact test was used to compare gender, frequencies of dia-
betic retinopathy, nephropathy, hypertension, and dyslip-
idemia, and percentage of patients with systemic vascular
score exceeding 2. In all cases, probability (P) values
of <0.05 were considered statistically significant. All
analyses were performed with the JMP Pro 10.0.2 for
Windows (SAS Institute, Cary, NC).
Results
Participant characteristics
We screened 92 Japanese patients with type 2 diabetes
(75 inpatients and 17 outpatients), excluded 17 patients
(they did not have eVFA data), and finally enrolled 75
patients in this study (58 inpatients and 17 outpatients; 41
males and 34 females; age, 64.8 ± 11.5 years; BMI 26.4 ±
5.8 kg/m2, WC; males 95 ± 14.4 cm, females 93.3 ± 11.9
cm; eVFA; males 151.4 ± 73.0 cm2, females 118.9 ± 55.5cm2). The enrolled patients were divided into two groups
based on eVFA. We defined the 53 patients (32 males and
21 females, 42 inpatients and 11 outpatients) with an
eVFA ≥100 cm2 as the visceral fat accumulation (+) group,
and the 22 remaining patients (9 males and 13 females,
16 inpatients and 6 outpatients) as the visceral fat accu-
mulation (−) group. Table 1 summarizes the baseline
characteristics of the patients.
Compared with the visceral fat accumulation (−) group,
the (+) group had significantly shorter duration of dia-
betes, higher serum C-peptide, higher TG, lower HDL-C,
higher UA levels, and higher percentage of dyslipidemia.
On the other hand, there were no significant differences
in age, sex, BP, glucose, HbA1c, T-Cho, LDL-C, Cr, eGFR,
uACR, max IMT, or mean IMT. Furthermore, there were
no significant differences between the two groups in the
prevalence of diabetic retinopathy, diabetic nephropathy,
hypertension, or medications.
Evaluation of systemic vascular score and serum adiponectin
levels
Figure 1 shows the distribution of systemic vascular
scores and serum adiponectin levels in each group. We
evaluated systemic arteriosclerosis by ultrasonography in
67 subjects (46 of (+) group and 21 of (−) group). The
systemic vascular score was significantly higher in the
visceral fat accumulation (+) group than in the (−) group
(Figure 1A). Furthermore, the percentage of subjects with
a systemic vascular score ≥2 was significantly higher in
the (+) group than in the (−) group (Figure 1B). Serum
adiponectin levels were measured in 62 subjects (44 of (+)
group and 18 of (−) group). The visceral fat accumulation
(+) group had significantly lower serum adiponectin levels
(10.33 ± 7.07 μg/ml) than the (−) group (5.82 ± 3.61 μg/ml)
(Figure 1C).
Assessment of eating behavior
Figure 2 shows a radar chart of eating behavior among all
study subjects, with the visceral fat accumulation (+) group
(continuous line) showing a significantly higher score than
the (−) group (dotted line) in “total score“, “recognition for
weight and constitution“, “external eating behavior“, “sense
of hunger“, “food preference“, and “regularity of eating
habit“ (Figure 2A).
Finally, we examined eating behavior between males
(n = 41) and females (n = 34). The differences between
the (+) and (−) groups in males were similar to those in
all subjects. On the other hand, in females (Figure 2C),
only “recognition for weight and constitution” showed a
significant difference between (+) and (−) groups.
Discussion
In this study, type 2 diabetic patients with visceral fat accu-
mulation showed 1) progression of systemic arteriosclerosis,
Table 1 Baseline characteristics
Variable All Visceral fat accumulation P value
(+) group (−) group
n (Males/Females) 75 (41/34) 53 (32/21) 22 (9/13) 0.14**
Age (years) 64.8 ± 11.5 63.0 ± 12.7 69.1 ± 6.2 0.09+
Body weight (kg) 69.2 ± 19.7 75.8 ± 19.5 53.1 ± 7.2 <0.001+
Body mass index (kg/m2) 26.4 ± 5.8 28.5 ± 5.4 21.3 ± 2.3 <0.001+
Waist circumferences (cm), all 94.2 ± 13.2 100.0 ± 11.5 81.3 ± 6.7 <0.001+
Males 95 ± 14.4 99.4 ± 12.9 79.3 ± 5.1 <0.001+
Females 93.3 ± 11.9 100.0 ± 9.1 82.7 ± 7.5 <0.001+
eVFA (cm2), all 136.7 ± 7.8 164.4 ± 60.0 70.0 ± 21.0 <0.001+
Males 151.4 ± 73.0 174.2 ± 66.0 70.7 ± 18.7 < 0.001+
Females 118.9 ± 55.5 149.4 ± 46.9 69.5 ± 23.3 < 0.001+
Duration of diabetes (years) 14.6 ± 10.5 12.7 ± 9.1 19.1 ± 12.4 0.04+
Diabetic retinopathy n = 19 (25%) 11 (21%) 8 (36%) 0.24*
Diabetic nephropathy n = 23 (31%) 18 (34%) 3 (14%) 0.27*
Hypertension n = 56 (75%) 39 (74%) 17 (77%) 1.00*
Dyslipidemia n = 58 (77%) 45 (85%) 13 (59%) 0.03*
Metabolic syndrome n = 52 (69%) 52 (98%) -
Systolic BP (mmHg) 128.1 ± 15.5 129.6 ± 15.6 124.5 ± 14.8 0.20#
Diastolic BP (mmHg) 73.9 ± 12.0 75.3 ± 12.0 70.7 ± 11.4 0.12#
Glucose (mg/dl) 150.1 ± 47.0 153.0 ± 49.0 142.9 ± 42.0 0.44+
HbA1c (NGSP) (%) 8.7 ± 1.7 8.8 ± 1.7 8.5 ± 1.9 0.33+
serum C-peptide (ng/ml) 2.2 ± 1.7 2.5 ± 1.8 1.4 ± 0.7 0.005+
T-Cho (mg/dl) 190.2 ± 40.5 194.0 ± 44.4 181.1 ± 27.8 0.35+
TG (mg/dl) 170.7 ± 233.8 199.3 ± 273.4 103.1 ± 40.1 0.001+
LDL-C (mg/dl) 105.6 ± 33.2 108.4 ± 36.0 99.0 ± 24.8 0.20#
HDL-C (mg/dl), all 50.2 ± 14.6 46.5 ± 12.4 58.9 ± 15.9 0.003#
UA (mg/dl) 5.5 ± 1.5 5.7 ± 1.6 5.0 ± 1.1 0.03#
eGFR (ml/min/1.73m2) 72.9 ± 19.6 73.9 ± 21.3 70.5 ± 15.1 0.42+
uACR (mg/gCr) 67.8 ± 147.8 72.6 ± 167.4 56.1 ± 84.0 0.97+
CCA max IMT (mm) 1.80 ± 0.80 1.75 ± 0.79 1.92 ± 0.82 0.39+
CCA mean IMT (mm) 0.98 ± 0.30 0.99 ± 0.32 0.98 ± 0.25 0.89+
Medications
for diabetes
Sulfonylureas n = 36 (48%) 26 (49%) 10 (45%) 0.81*
Glinides n = 6 (8%) 4 (8%) 2 (9%) 1.00*
Biguanides n = 24 (32%) 18 (34%) 6 (27%) 0.79*
Alpha-GIs n = 14 (19%) 8 (15%) 6 (27%) 0.33*
Thiazolidinediones n = 6 (8%) 4 (8%) 2 (9%) 1.00*
DPP-4 inhibitors n = 22 (29%) 17 (32%) 5 (23%) 0.58*
Insulin n = 15 (20%) 10 (19%) 5 (23%) 0.76*
GLP-1 analogs n = 8 (11%) 7 (13%) 1 (5%) 0.42*
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for hypertension
ACEI/ARBs n = 37 (49%) 26 (49%) 11 (50%) 1.00*
for dyslipidemia
Statins n = 37 (49%) 26 (49%) 11 (50%) 1.00*
Data are mean ± SD [minimum-maximum], or number of subjects (frequency (%)). eVFA; estimated visceral fat area, BP; blood pressure, NGSP; National
Glycohemoglobin Standardization Program, T-Cho; total cholesterol, TG; triglyceride, LDL-C; LDL cholesterol, HDL-C; HDL cholesterol, UA; uric acid, eGFR; estimated
glomerular filtration rate, uACR; urine albumin-to-creatinine ratio, CCA; common carotid artery, IMT; intima-media thickness, Alpha-GI; alpha-glucosidase inhibitor,
DPP-4; dipeptidyl peptidase-4, GLP-1; glucagon-like peptide-1, ACEI; angiotensin-converting enzyme inhibitor, ARB; angiotensin II receptor blocker. **Fisher’s exact
test (males vs females), +; Mann-Whitney’s U test ((+) group vs (−) group), *Fisher’s exact test ((+) group vs (−) group), #; Welch’s t-test ((+) group vs. (−) group).
Figure 1 Visceral fat accumulation and (A) number of subjects,
(B) percentage of subjects with systemic vascular score ≥2, (C)
serum total adiponectin levels. Each P value is calculated with:
(A); Cochran-Armitage trend test, (B); Fischer’s exact test, (C);
Mann-Whitney’s U test. Data are mean ± SD.
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behaviors from those without visceral fat accumulation.
Systemic arteriosclerosis and serum adiponectin levels in
type 2 diabetic patients with visceral fat accumulation
We have shown that systemic arteriosclerosis predicts
CAD development in patients with type 2 diabetes [15],
and that metabolic syndrome is a determinant of systemic
arteriosclerosis [1]. Moreover, hypoadiponectinemia corre-
lates with visceral fat accumulation [22] and predicts the
risk of CAD in Japanese type 2 diabetic patients [7]. Adi-
ponectin is an adipocyte-derived plasma protein, which
our group identified through a human cDNA project
targeting adipose tissue [23] and which shows various
anti-atherogenic effects in vascular endothelial cells,
smooth muscle cells, and macrophages in cell culture
[24-26]. Furthermore, administration of adiponectin with
adenovirus vector suppressed the progression of arterio-
sclerosis in apolipoprotein E-knockout mouse, which is
the animal model for arteriosclerosis [27].
Although several research groups reported that adipo-
nectin correlates with diabetes mellitus and/or arterio-
sclerosis, few studies have compared serum adiponectin
levels between type 2 diabetic patients with visceral fat
accumulation and those without. The present study there-
fore provides the first evidence to clarify the state of hypoa-
diponectinemia in type 2 diabetic patients with visceral fat
accumulation, and to suggest that these states together
could be associated with the progression of systemic ar-
teriosclerosis. Hypoadiponectinemia is associated with type
2 diabetes, metabolic syndrome, and atherosclerosis [28].
Recently, we reported that C1q-binding adiponectin levels
were high in patients with ACS, suggesting the possibility
of a protective role of adiponectin against activated-
complement system in ACS patients. On the other hand, it
is reported that high serum adiponectin is correlated with
cardiovascular mortality [29]. The patients with heart
failure or renal failure had also high plasma adiponec-
tin levels [30,31]. It is possible that the plasma adiponec-
tin levels were affected by various pathophysiological
conditions. Further studies are needed to clarify the
association between plasma adiponectin levels and
clinical diseases.
Figure 2 Comparisons of eating behavior between (+) group (the subjects with visceral fat accumulation, solid line) and (−) group
(those without, dotted line), (A) in all subjects, (B) in male subjects, (C) in female subjects. *; P < 0.05, **; P < 0.01, (+) group versus (−)
group, calculated with Mann-Whitney’s U test.
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(BMI <25 kg/m2) subjects had visceral fat accumulation
(eVFA ≥100 cm2) and that the frequency of two or more as
a vascular score is significantly higher in such patients thanin non-obese patients without visceral fat accumulation
(BMI <25 kg/m2 and eVFA <100 cm2) (87.5% vs. 42.9%,
respectively), while their serum adiponectin levels tended to
be lower (5.96 ± 1.9 vs. 10.23 ± 7.14 μg/ml, P = 0.09). Thus,
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even if they are not obese, might still develop systemic
arteriosclerosis and dysregulation of adipocytokines, and
are considered to be at high risk of cardiovascular diseases.
Asian and Japanese populations could be easily affected
with type 2 diabetes mellitus, including those with relatively
low BMIs, compared to Caucasians [32], and since many
such patients are non-obese, assessment of visceral fat
accumulation is important to identify the patients with
multiple risk factors of cardiovascular diseases [6,33], and
particularly to identify patients who could possibly improve
their diabetes and prevent arteriosclerosis through decreas-
ing multiple cardiovascular risk factors by reduction of
accumulated visceral fat.
This study found no association between visceral fat
accumulation and diabetic microangiopathies, such as
retinopathy and nephropathy. Several research groups
have reported that glycemic control and the duration of
diabetes significantly influence the onset and progression
of diabetic microangiopathy [34-36], and herein, the dur-
ation of diabetes was significantly shorter in subjects
with visceral fat accumulation than in those without,
whereas HbA1c levels were not different. Dirani M et al.
demonstrated in prospective study that obese diabetic
patients were more likely to have diabetic retinopathy [37],
while a recent paper reported no significant association
between obesity and diabetic retinopathy [38], suggesting
that the association between obesity and diabetic micro-
angiopathy seems to be still unclear. Thus, evaluation of
microangiopathies should also be carried out, regardless of
the patients’ visceral fat accumulation status.
Eating behaviors and visceral fat accumulation
We also demonstrated different eating behaviors in type 2
diabetic patients with visceral fat accumulation compared
to those without visceral fat accumulation, including “food
preference”, “eating style”, and “sense of hunger”, and
these result were more obvious in male patients. Kozuka
et al. [39] reported that hypothalamic endoplasmic
reticulum stress was associated with preference for high
fat food, which is one of the eating behaviors assessed.
Studies from our group have also shown that treatment
with liraglutide, a glucagon-like peptide-1 (GLP-1) ana-
logue, improved not only glycemic control, but also obes-
ity, possibly through affecting eating behavior (especially
“sense of hunger” and “eating style”) in Japanese type 2
diabetic patients, using the radar chart [20,21]. Glucagon-
like peptides have both peripheral effects, such as gastric
motility, and central effects, such as inhibition of appetite,
through targeting the arcuate nucleus and other hypothal-
amic lesions [40]. Accordingly, body weight reduction is
effective for the treatment of type 2 diabetes with visceral
fat accumulation [41], and the reduction of visceral and
subcutaneous fat was reported to correlate with theelevation of adiponectin levels [42]. Body weight reduction
can be achieved through conventional diet and exercise
therapy as well as cognitive therapy [10]. A questionnaire-
based radar chart of eating behaviors could therefore be a
useful tool for the treatment of type 2 diabetic patients
with visceral fat accumulation, by helping patients to visu-
ally recognize their eating behaviors and to modify their
own eating behaviors by themselves. Although it is pos-
sible that there is gender difference in the assessment of
eating behaviors using the questionnaire, its etiology
remains unclear in the present study.
Taken together, the present results demonstrated the
importance of evaluating VFA in type 2 diabetic patients,
and for those with visceral fat accumulation, physicians
may need to screen for systemic arteriosclerosis more
intensively and consider support for patients in modifying
their eating behaviors.
This study has several limitations. The study was not pro-
spective in design, included a relatively small population,
and was performed in a single institution. The influence of
gender, ethnicities, and other residual or unmeasured fac-
tors which affect several cardiometabolic factors and eating
behaviors cannot be fully excluded. Further prospective
studies of larger populations are needed in the future.
Conclusions
In conclusion, type 2 diabetic patients with visceral fat accu-
mulation showed more advanced systemic arteriosclerosis,
lower serum adiponectin levels, and differences in eating be-
havior, compared to those without visceral fat accumulation.
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